World's Best Scientists 2026 revealed!
Giuliano Rizzardini

Giuliano Rizzardini

D-Index & Metrics

Microbiology

D-Index
48
Citations
11980
World Ranking
4636
National Ranking
150

Giuliano Rizzardini publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Giuliano Rizzardini sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 310 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Giuliano Rizzardini D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Giuliano Rizzardini sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 48 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Giuliano Rizzardini is affiliated with ASST Fatebenefratelli Sacco in Italy and has contributed extensively to medical research with a focus on infectious diseases. Their work covers a broad range of topics primarily within medicine, with significant efforts in infectious diseases, epidemiology, virology, hepatology, and molecular biology.

Their research frequently appears in journals such as Clinical Infectious Diseases, Journal of Medical Virology, Digestive and Liver Disease, Journal of Hepatology, and Journal of Infection. These venues reflect the core interests of their publications in infectious and liver diseases.

Among the main topics of Giuliano Rizzardini's research are:

  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • HIV/AIDS drug development and treatment
  • Hepatitis C virus research
  • HIV Research and Treatment
  • Poxvirus research and outbreaks
  • COVID-19 and healthcare impacts

Frequent co-authors in their work include Spinello Antinori, Andrea Giacomelli, Massimo Galli, Anna Lisa Ridolfo, and Maria Vittoria Cossu. Collaboration with these colleagues has resulted in numerous publications and contributed to a concentrated expertise in their research fields.

Significant papers authored by or involving Giuliano Rizzardini include:

  • "Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study," 2020, Clinical Infectious Diseases
  • "Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression," 2020, New England Journal of Medicine
  • "COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?" 2020, Clinical and Experimental Rheumatology
  • "Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study," 2020, The Lancet
  • "30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study," 2020, Pharmacological Research

The combination of diverse expertise areas and broad publication record highlights Giuliano Rizzardini's involvement in addressing clinical challenges related to viral infections, particularly in the context of COVID-19 and HIV. Their work reflects an integration of clinical research, epidemiology, and therapeutic development, which contributes to the understanding and management of infectious diseases globally.

Best Publications

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study.

    Andrea Giacomelli;Laura Pezzati;Federico Conti;Dario Bernacchia

  • ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

    Peter Ferenci;David Bernstein;Jacob Lalezari;Daniel Cohen

  • COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

    Piercarlo Sarzi-Puttini;Valeria Giorgi;Silvia Sirotti;Daniela Marotto

  • Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

    Susan Swindells;Jaime-Federico Andrade-Villanueva;Gary J. Richmond;Giuliano Rizzardini

  • Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study

    Hans-Jürgen Stellbrink;Chloe Orkin;Jose Ramon Arribas;Juliet Compston

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

    Edgar T Overton;Gary Richmond;Giuliano Rizzardini;Hans Jaeger

  • Early Impairment of Gut Function and Gut Flora Supporting a Role for Alteration of Gastrointestinal Mucosa in Human Immunodeficiency Virus Pathogenesis

    Andrea Gori;Andrea Gori;Camilla Tincati;Giuliano Rizzardini;Carlo Torti

  • 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study.

    Andrea Giacomelli;Anna Lisa Ridolfo;Laura Milazzo;Letizia Oreni

  • Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study.

    Giuliano Rizzardini;Dorte Eskesen;Philip C. Calder;Amedeo Capetti

  • Retinal findings in patients with COVID-19: Results from the SERPICO-19 study.

    Alessandro Invernizzi;Alessandro Invernizzi;Alessandro Torre;Salvatore Parrulli;Federico Zicarelli

  • Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.

    Spinello Antinori;Maria Vittoria Cossu;Anna Lisa Ridolfo;Roberto Rech

  • Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non–AIDS-Defining Events in a Large Cohort of HIV-Infected Patients

    Miriam Lichtner;Paola Cicconi;Serena Vita;Alessandro Cozzi-Lepri

  • Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness

    Stefania Piconi;Daria Trabattoni;Cristina Luraghi;Edoardo Perilli

  • Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial

    A. Gori;G. Rizzardini;B. van't Land;K. B. Amor

  • Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.

    Stefania Piconi;Serena Parisotto;Giuliano Rizzardini;Simone Passerini

  • AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy

    Nicolas Mounier;Michele Spina;Jean Gabarre;Martine Raphael

  • Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.

    Stefania Piconi;Daria Trabattoni;Andrea Gori;Serena Parisotto

  • Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.

    Valentina Morena;Laura Milazzo;Letizia Oreni;Giovanna Bestetti

  • Probiotics reduce gut microbial translocation and improve adult atopic dermatitis.

    Enrico Iemoli;Daria Trabattoni;Serena Parisotto;Linda Borgonovo

  • Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

    Alessandro Cozzi-Lepri;Marc Noguera-Julian;Francesca Di Giallonardo;Rob Schuurman

  • Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.

    Matteo Bassetti;Nadia Castaldo;Annamaria Cattelan;Cristina Mussini

  • Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

    Joel E. Gallant;Ellen Koenig;Jaime Andrade-Villanueva;Ploenchan Chetchotisakd

  • Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy.

    Gianguglielmo Zehender;Alessia Lai;Annalisa Bergna;Luca Meroni

  • Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections.

    Dario Cattaneo;Giovanna Orlando;Valeria Cozzi;Laura Cordier

Frequent Co-Authors

Massimo Galli
Massimo Galli University of Milan
Carlo Federico Perno
Carlo Federico Perno University of Milan
Mario Clerici
Mario Clerici University of Milan
Antonella d'Arminio Monforte
Antonella d'Arminio Monforte University of Milan
Andrea Antinori
Andrea Antinori Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Massimo Andreoni
Massimo Andreoni University of Rome Tor Vergata
Andrea Gori
Andrea Gori University of Milan
Massimo Puoti
Massimo Puoti University of Milano-Bicocca
Adriano Lazzarin
Adriano Lazzarin Vita-Salute San Raffaele University
Spinello Antinori
Spinello Antinori University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Microbiology in the USA opens doors to various related career pathways, especially in health and medical fields. For those interested in patient-centered roles, becoming a functional medicine nurse practitioner offers a unique blend of microbiology knowledge and holistic patient care, emphasizing personalized treatment plans.

On the administrative side, the healthcare industry demands expertise in managing health data efficiently. Professionals can explore a certification as a certified professional coder certification to accurately translate healthcare services into standardized codes, a critical skill for billing and compliance.

Those aiming for leadership or organizational roles should consider the evolving field of health information management. Entry-level opportunities often depend on the right qualifications, so checking out the health information management salary entry-level outlook provides useful insight into job expectations and compensation.

Many students prefer flexible learning paths, and enrolling in an online cahiim accredited health information management degree program ensures a credible education that meets industry standards while balancing other commitments.

Best Scientists Citing Giuliano Rizzardini

Trending Scientists